What is Zacks Research's Estimate for Exelixis Q2 Earnings?

Exelixis, Inc. (NASDAQ:EXEL - Free Report) - Equities researchers at Zacks Research lifted their Q2 2025 earnings per share (EPS) estimates for shares of Exelixis in a research report issued to clients and investors on Monday, March 3rd. Zacks Research analyst E. Bagri now forecasts that the biotechnology company will post earnings per share of $0.47 for the quarter, up from their prior forecast of $0.46. The consensus estimate for Exelixis' current full-year earnings is $2.04 per share. Zacks Research also issued estimates for Exelixis' FY2027 earnings at $3.20 EPS.

A number of other research analysts also recently weighed in on EXEL. HC Wainwright reissued a "buy" rating and issued a $40.00 price objective on shares of Exelixis in a research note on Thursday, February 13th. StockNews.com raised Exelixis from a "buy" rating to a "strong-buy" rating in a research note on Wednesday, February 19th. Barclays raised their price objective on Exelixis from $25.00 to $29.00 and gave the company an "equal weight" rating in a research note on Thursday, February 13th. Stifel Nicolaus raised their price objective on Exelixis from $30.00 to $36.00 and gave the company a "hold" rating in a research note on Wednesday, February 12th. Finally, Citigroup raised their price objective on Exelixis from $38.00 to $45.00 and gave the company a "buy" rating in a research note on Wednesday, February 12th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $37.24.

Remove Ads

Exelixis Price Performance

Shares of EXEL stock traded up $0.37 during trading on Wednesday, reaching $38.58. The company had a trading volume of 1,838,259 shares, compared to its average volume of 2,073,747. The firm's 50 day simple moving average is $34.99 and its two-hundred day simple moving average is $32.08. Exelixis has a one year low of $20.14 and a one year high of $39.30. The company has a market capitalization of $10.80 billion, a PE ratio of 21.80, a PEG ratio of 1.13 and a beta of 0.57.

Exelixis (NASDAQ:EXEL - Get Free Report) last posted its quarterly earnings results on Tuesday, February 11th. The biotechnology company reported $0.48 earnings per share for the quarter, missing analysts' consensus estimates of $0.51 by ($0.03). Exelixis had a return on equity of 23.52% and a net margin of 24.04%.

Institutional Investors Weigh In On Exelixis

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. raised its position in shares of Exelixis by 0.4% during the fourth quarter. Vanguard Group Inc. now owns 29,429,252 shares of the biotechnology company's stock worth $979,994,000 after acquiring an additional 121,750 shares during the last quarter. LSV Asset Management raised its position in shares of Exelixis by 0.8% during the fourth quarter. LSV Asset Management now owns 8,169,847 shares of the biotechnology company's stock worth $272,056,000 after acquiring an additional 67,470 shares during the last quarter. Fuller & Thaler Asset Management Inc. raised its position in shares of Exelixis by 10.2% during the fourth quarter. Fuller & Thaler Asset Management Inc. now owns 7,630,940 shares of the biotechnology company's stock worth $254,110,000 after acquiring an additional 708,312 shares during the last quarter. Invesco Ltd. raised its position in shares of Exelixis by 308.1% during the fourth quarter. Invesco Ltd. now owns 3,975,241 shares of the biotechnology company's stock worth $132,376,000 after acquiring an additional 3,001,204 shares during the last quarter. Finally, AQR Capital Management LLC raised its position in shares of Exelixis by 25.7% during the fourth quarter. AQR Capital Management LLC now owns 3,967,005 shares of the biotechnology company's stock worth $132,101,000 after acquiring an additional 810,857 shares during the last quarter. Institutional investors own 85.27% of the company's stock.

Insider Activity at Exelixis

In other Exelixis news, Director Bob Oliver sold 18,647 shares of Exelixis stock in a transaction on Tuesday, February 25th. The stock was sold at an average price of $37.25, for a total value of $694,600.75. Following the completion of the transaction, the director now owns 33,514 shares in the company, valued at approximately $1,248,396.50. The trade was a 35.75 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Mary C. Beckerle sold 12,210 shares of Exelixis stock in a transaction on Friday, February 14th. The shares were sold at an average price of $34.88, for a total value of $425,884.80. Following the completion of the transaction, the director now owns 30,406 shares of the company's stock, valued at approximately $1,060,561.28. The trade was a 28.65 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 140,343 shares of company stock valued at $5,177,234 in the last 90 days. 2.85% of the stock is owned by corporate insiders.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.